Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises KKR in connection with an additional investment in Söderberg & Partners
Mandate

Vinge advises KKR in connection with an additional investment in Söderberg & Partners

June 27, 2023 M&A

Söderberg & Partners has raised new capital for its continued international expansion. The current minority owner, KKR, has invested an additional amount of SEK 2.3 billion through a new issue of shares. Following the new issue of shares, KKR will remain as a significant minority shareholder in Söderberg & Partners together with TA Associates. However, control of the company remains with its founders and chairman of the board of directors.

Vinge’s team consisted of Christina Kokko, Samra Tesser and Maximilian Bengtsson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026